Verve Therapeutics Inc (NASDAQ:VERV) — Market Cap & Net Worth
Market Cap & Net Worth: Verve Therapeutics Inc (VERV)
Verve Therapeutics Inc (NASDAQ:VERV) has a market capitalization of $994.04 Million ($994.04 Million) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8795 globally and #2508 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Verve Therapeutics Inc's stock price $11.13 by its total outstanding shares 89312200 (89.31 Million). Review Verve Therapeutics Inc (VERV) financial obligations to assess the company's total debt and financial obligations.
Verve Therapeutics Inc Market Cap History: 2021 to 2025
Verve Therapeutics Inc's market capitalization history from 2021 to 2025. Data shows change from $3.29 Billion to $994.04 Million (-22.63% CAGR).
Index Memberships
Verve Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.04% | #257 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #953 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.06% | #148 of 263 |
Weight: Verve Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Verve Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Verve Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
15.58x
Verve Therapeutics Inc's market cap is 15.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.73 Billion | $1.94 Million | -$157.39 Million | 890.36x | N/A |
| 2023 | $1.25 Billion | $11.76 Million | -$200.07 Million | 105.89x | N/A |
| 2024 | $503.72 Million | $32.33 Million | -$198.71 Million | 15.58x | N/A |
Competitor Companies of VERV by Market Capitalization
Companies near Verve Therapeutics Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Verve Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Verve Therapeutics Inc Historical Marketcap From 2021 to 2025
Between 2021 and today, Verve Therapeutics Inc's market cap moved from $3.29 Billion to $ 994.04 Million, with a yearly change of -22.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $994.04 Million | +97.34% |
| 2024 | $503.72 Million | -59.54% |
| 2023 | $1.25 Billion | -27.96% |
| 2022 | $1.73 Billion | -47.52% |
| 2021 | $3.29 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 24th, 2026 the market cap of Verve Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $994.04 Million USD |
| MoneyControl | $994.04 Million USD |
| MarketWatch | $994.04 Million USD |
| marketcap.company | $994.04 Million USD |
| Reuters | $994.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Verve Therapeutics Inc
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hyper… Read more